Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Orthocell Ltd ( (AU:OCC) ) is now available.
Orthocell Limited has issued 230,770 fully paid ordinary shares at $1.30 each as part of a capital raising initiative. This move aligns with their strategy to enhance financial resources for ongoing product development and market expansion, potentially strengthening their position in the regenerative medicine industry.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
More about Orthocell Ltd
Orthocell Limited is a regenerative medicine company focused on developing products for the repair of bone and soft tissue injuries. Their portfolio includes collagen medical devices for dental and orthopedic applications, with products like Striate+™ and Remplir™ gaining international clearance and distribution. The company is also advancing autologous cell therapies for tendon and cartilage regeneration.
Average Trading Volume: 781,534
Technical Sentiment Signal: Buy
Current Market Cap: A$297.9M
Learn more about OCC stock on TipRanks’ Stock Analysis page.